sr141716 has been researched along with Colorectal Neoplasms in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bifulco, G; Bifulco, M; Bizzarro, V; Feoli, A; Fiore, D; Franceschelli, S; Gazzerro, P; Laezza, C; Lauro, G; Piscopo, C; Proto, MC; Sbardella, G; Tosco, A | 1 |
| Bifulco, M; Borrelli, F; Gazzerro, P; Grimaldi, C; Izzo, AA; Laezza, C; Malfitano, AM; Pisanti, S; Proto, MC; Santoro, A | 1 |
| Moyer, MP; Robertson, DA; Ward, SG; Wright, KL | 1 |
| Bifulco, M; Gazzerro, P; Laezza, C; Malfitano, AM; Pisanti, S; Santoro, A | 1 |
4 other study(ies) available for sr141716 and Colorectal Neoplasms
| Article | Year |
|---|---|
Inhibition of Wnt/β-Catenin pathway and Histone acetyltransferase activity by Rimonabant: a therapeutic target for colon cancer.
Topics: Animals; Cannabinoid Receptor Antagonists; Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplasms; Disease Models, Animal; Female; Heterografts; Histone Acetyltransferases; Humans; Mice, SCID; Models, Biological; Neoplasm Transplantation; Rimonabant; Treatment Outcome; Wnt Signaling Pathway | 2017 |
Rimonabant inhibits human colon cancer cell growth and reduces the formation of precancerous lesions in the mouse colon.
Topics: Animals; Apoptosis; Aurora Kinase B; Aurora Kinases; Azoxymethane; Blotting, Western; Cannabinoid Receptor Antagonists; Cell Cycle; Cell Proliferation; Checkpoint Kinase 1; Chromosome Aberrations; Colony-Forming Units Assay; Colorectal Neoplasms; Cyclin B; Cyclin B1; DNA Damage; Female; Humans; Mice; Mice, Inbred C57BL; Mitotic Index; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Polyploidy; Precancerous Conditions; Protein Kinases; Protein Serine-Threonine Kinases; Pyrazoles; Rimonabant; Tumor Cells, Cultured | 2009 |
Long term cannabinoid receptor (CB1) blockade in obesity: implications for the development of colorectal cancer.
Topics: Adenoma; Anti-Obesity Agents; Apoptosis; Carcinoma; Cell Transformation, Neoplastic; Colorectal Neoplasms; Dronabinol; Drug Inverse Agonism; Humans; Inflammatory Bowel Diseases; Intestinal Mucosa; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant | 2008 |
Reply to the letter to the editor "Long-term cannabinoid receptor (CB1) blockade in obesity: implications for the development of colorectal cancer".
Topics: Animals; Anti-Inflammatory Agents; Anti-Obesity Agents; Antineoplastic Agents; Carcinoma; Cell Survival; Colorectal Neoplasms; Dose-Response Relationship, Drug; Humans; Mice; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Time Factors | 2008 |